10 results about "Shigella sonnei" patented technology

The invention relates to application of a scavenger receptor A antibody in preparation of a medicine for inhibiting plasmodium transmission, and belongs to the technical field of malaria prevention and treatment. Aiming at the technical problem that in the prior art, the drug resistance of plasmodium to drugs and the resistance of mosquito vector to insecticides are increasingly serious, so that the malaria propagation control effect is reduced, the invention provides a scavenger receptor A antibody which is specifically combined with a scavenger receptor A on the surface of macrophage to inhibit the phagocytic function of the scavenger receptor A, so that the control effect of malaria propagation is improved. Therefore, the proliferation of antimalarial active bacteria (such as Elizabeth, shigella sonnei or klebsiella oxytoca) in the stomach of the anopheles is promoted, and the development of plasmodium in the midgut of the anopheles is indirectly blocked. The antibody can be used alone or in combination with a Pfs25 antibody. The anopheles infection rate and the number of oocysts are remarkably reduced (for example, the infection rate is reduced from 81.7% to 6%), an eco-friendly biological control mode which is not prone to drug resistance is provided, and a new strategy is provided for malaria transmission blocking.

The invention discloses a group of antibacterial polypeptides aiming at gram-negative bacteria, and belongs to the technical field of biological medicines. According to the invention, a group of antibacterial peptides is obtained through screening, and the antibacterial peptides have good broad-spectrum antibacterial performance on escherichia coli, salmonella typhimurium, pseudomonas aeruginosa, klebsiella pneumoniae, shigella sonnei and stenotrophomonas maltophilia. Wherein the hemolytic activity and toxicity of the antibacterial peptides 11A-1, 11A-4 and 11A-5 are lower than therapeutic concentration threshold values, and the antibacterial peptides 11A-1, 11A-4 and 11A-5 can be used for preparing drugs or medical products for treating multi-drug-resistant bacterial infection.

The invention provides a Shigella sonnei bacteriophage vBSsPLW and application thereof, and belongs to the technical field of microorganisms, the bacteriophage is preserved in Guangdong Microbiological Culture Collection Center, the address is 59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, Institute of Microbiology, Guangdong Academy of Sciences, the preservation date is June 17, 2025, and the preservation number is GDMCC No: 66526-B1. The phage vBSsPLW provided by the invention is high in titer, short in incubation period and good in environmental stability, and still has relatively high activity when the temperature reaches 70 DEG C; the recombinant shigella sonnei strain has the advantages that the recombinant shigella sonnei strain is stable in titer change within the pH range of 6.0-11.0, has a very strong bacteriostatic effect on shigella sonnei under different infection complex conditions, and can achieve the bacteriostatic purpose by inhibiting the formation of a shigella sonnei biofilm. The method has strong application potential in food preservation, biology, medicine and other aspects.

This invention provides a highly lytic Shigella phage and its applications, belonging to the field of bioengineering technology. The phage is named vB-SsoS-Q1, classified as Shigella sonnei phage, and deposited at the China General Microbiological Culture Collection Center (CGMCC) with accession number CGMCC No. 45414. This phage is a double-stranded DNA phage with an icosahedral head approximately 75 nm long and 70 nm wide, possessing a retractable tail. It belongs to the class Tailed Phages, with a full-length gene of 50326 bp. It does not contain virulence or drug resistance genes, exhibits highly efficient lytic ability, and can lyse broadly against Shigella and Escherichia coli. This phage can be applied to prevent and treat bacterial diarrhea in livestock and poultry, for the biopreservation of fresh meat, dairy products, and other foods, effectively controlling contamination by multidrug-resistant Shigella, and providing a safe and efficient new solution to replace antibiotics.

The invention belongs to the field of gene detection, and particularly relates to a characteristic gene combination for predicting antibiotic susceptibility phenotype of shigella sonnei, a kit and application of the characteristic gene combination. The drug sensitive phenotype of shigella sonnei to antibiotics is judged by detecting specific genes or mutation, the method has the advantages of high accuracy, high sensitivity and high specificity, and accurate diagnosis and treatment of infection are facilitated.

Disclosed is the attenuated Salmonella typhi vaccine Ty21a utilized as a vector for Shigella and / or enterotoxogenic E. coli genes stably integrated in the Ty21a chromosome. These genes include a heterologous Shigella sonnei O-antigen biosynthetic gene region that comprises the wzz gene and expresses Shigella sonnei form 1 O-antigen, as well as a heterologous acid resistance biosynthetic gene system comprising a YbaS gene, which enables increased stability of the Ty21a vector at pH 2.5 relative to Ty21a without the integrated acid resistance biosynthetic gene system.

The invention provides a vBSsPLW-coated Fe3O4 composite material, a preparation method thereof and application of the vBSsPLW-coated Fe3O4 composite material in detection of Shigella sonnei, and belongs to the technical field of microbiological detection. The preparation method comprises the following steps: activating prepared magnetic Fe3O4, adding a shigella sonnei bacteriophage vBSsPLW solution, mixing and incubating to obtain a vBSsPLW-coated Fe3O4 composite material, and quantitatively detecting bacteria by utilizing the influence of shigella sonnei on the activity of enzyme-like peroxides of the vBSsPLW-coated Fe3O4 composite material, the lowest detection concentration is 12 CFU / mL, the color development time is only 15 minutes, and other non-specific bacteria cannot be recognized. The kit has the advantages of strong specificity, high sensitivity, short time consumption, visualization and the like, and can meet the detection requirements of shigella sonnei in different food matrixes.

The present invention, in embodiments, relates to a multivalent vaccine comprising a combination of two or more different monovalent Shigella oligosaccharide protein conjugates and an adjuvant. One of the vaccine components can be a Shigella sonnei oligosaccharide- protein conjugate and the other three can be Shigella flexneri oligosaccharide-protein conjugates, specifically, S. flexneri 2a, S. flexneri 3a and S. flexneri 6, respectively. All conjugates feature sOS components acting as surrogates of the heterogeneous Shigella surface polysaccharide antigens characteristic of each one of the selected Shigella serotypes. The multivalent vaccine of the present invention is made for the prevention and / or treatment of disease caused by Shigella, in particular S. sonnei and S. flexneri.

The invention is concerning a medical preparation comprising bicyclic heptapeptides for use in vertebrates or humans suffering from an infection caused by Gram-negative bacteria like Pseudomonas aeruginosa, Klebsiella pneumoniae, Acineto-bacter baumannii, Neisseria gonorrhoeae, Chlamydia trachomatis, Shigella sonnei, Salmonella enterica Typhimurium LT2, Enterobacter spp., Bifidobacterium longum, Bacteroides fragilis, Lactobacillus reuteri, Enterococcus spp., Yersinia pestis and numerous other Gram-negative bacteria.

The present invention discloses a polypeptide drug for use against Gram-negative bacteria and its application, belonging to the field of biomedicine. The antimicrobial peptide screened and obtained by the present invention has broad-spectrum antibacterial properties, with MICs of 16 μg / mL, 2 μg / mL, 16 μg / mL, 4 μg / mL, 2 μg / mL, and 4 μg / mL against Escherichia coli, Salmonella typhimurium, Pseudomonas aeruginosa, Klebsiella pneumoniae, Shigella sonnei, and Stenotrophomonas maltophilia, respectively. Its hemolytic and toxic properties are below the therapeutic concentration threshold, and it can be used to prepare drugs or medical products for treating multidrug-resistant bacterial infections.